Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) through Partnership with Pharmacy Services Provider

RADNOR, Pa., May 13, 2022 /PRNewswire/ — Following the launch of QUVIVIQ™ (daridorexant) CIV on May 2, Idorsia Pharmaceuticals, U.S. Inc. announced today that the first wave of patients has been prescribed the product through a pharmacy services provider. The pharmacy services provider…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.